体外研究 CB-183,315、万古霉素和甲硝唑对 556 株艰难梭菌、445 株其他肠道厌氧菌和 56 株肠杆菌科细菌的活性。
In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.
机构信息
RM Alden Research Lab, Culver City, California, USA.
出版信息
Antimicrob Agents Chemother. 2012 Mar;56(3):1613-5. doi: 10.1128/AAC.05655-11. Epub 2011 Dec 19.
Abstract
MICs of CB-183,315, a novel lipopeptide antibiotic, vancomycin, and metronidazole were determined for intestinal anaerobes and Enterobacteriaceae. The MIC(90)s for Gram-negative anaerobes were >8,192, 8,192, and 4 μg/ml for CB-183,315, vancomycin, and metronidazole, respectively. Against Enterobacteriaceae, the MIC(90)s were >8,192 μg/ml, 1,024 μg/ml, and 1,024 μg/ml, respectively. The CB-183,315 MIC(90) for Clostridium difficile was 0.5 μg/ml. Its lack of activity against normal fecal organisms makes it a promising new agent for treating C. difficile.
摘要
CB-183,315 是一种新型脂肽类抗生素，我们测定了其对肠道厌氧菌和肠杆菌科的最低抑菌浓度（MIC）。对革兰氏阴性厌氧菌而言，CB-183,315、万古霉素和甲硝唑的 MIC(90)分别为>8,192、8,192 和 4 μg/ml。对肠杆菌科，MIC(90)分别为>8,192 μg/ml、1,024 μg/ml 和 1,024 μg/ml。CB-183,315 对艰难梭菌的 MIC(90)为 0.5 μg/ml。它对正常粪便微生物无活性，这使其成为治疗艰难梭菌的一种有前途的新型药物。
相似文献
1
In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.体外研究 CB-183,315、万古霉素和甲硝唑对 556 株艰难梭菌、445 株其他肠道厌氧菌和 56 株肠杆菌科细菌的活性。
Antimicrob Agents Chemother. 2012 Mar;56(3):1613-5. doi: 10.1128/AAC.05655-11. Epub 2011 Dec 19.
2
Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens.新型环状脂肽 CB-183,315 对耐药性艰难梭菌和其他革兰氏阳性需氧和厌氧肠道病原体的活性。
Antimicrob Agents Chemother. 2012 Jun;56(6):3448-52. doi: 10.1128/AAC.06257-11. Epub 2012 Mar 5.
3
Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.LFF571 对艰难梭菌和 630 株其他需氧和厌氧肠道菌株的体外比较活性。
Antimicrob Agents Chemother. 2012 May;56(5):2493-503. doi: 10.1128/AAC.06305-11. Epub 2012 Jan 30.
4
In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile.新型酮内酯 RBx 14255 对艰难梭菌的体外和体内活性。
Antimicrob Agents Chemother. 2012 Nov;56(11):5986-9. doi: 10.1128/AAC.00015-12. Epub 2012 Aug 6.
5
In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.雷莫拉宁、替考拉宁、万古霉素、利奈唑胺、杆菌肽及其他四种抗菌药物对肠道厌氧菌的体外活性
Antimicrob Agents Chemother. 2003 Jul;47(7):2334-8. doi: 10.1128/AAC.47.7.2334-2338.2003.
6
Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium.舒洛托霉素在艰难梭菌、粪肠球菌和屎肠球菌中显示出较低的体外耐药频率和快速杀菌活性。
Antimicrob Agents Chemother. 2014 Jul;58(7):3976-82. doi: 10.1128/AAC.00124-14. Epub 2014 May 5.
7
In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile.新型脂肽类抗生素 CB-183,315 的体外和体内特性研究，用于治疗艰难梭菌感染。
Antimicrob Agents Chemother. 2012 Oct;56(10):5023-30. doi: 10.1128/AAC.00057-12. Epub 2012 Jul 16.
8
Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment.艰难梭菌生物膜分析：成像与抗菌治疗。
J Antimicrob Chemother. 2018 Jan 1;73(1):102-108. doi: 10.1093/jac/dkx353.
9
Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates.比较 SMT19969 一种新的抗菌药物对艰难梭菌和 350 种需氧和厌氧肠道菌群分离株的体外活性。
Antimicrob Agents Chemother. 2013 Oct;57(10):4872-6. doi: 10.1128/AAC.01136-13. Epub 2013 Jul 22.
10
Analysis of anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations.分析单独及联合使用时，短小杆菌素 CD、万古霉素、甲硝唑、瑞他莫林和 actagardine 对艰难梭菌的抑制活性。
Antimicrob Agents Chemother. 2013 Jun;57(6):2882-6. doi: 10.1128/AAC.00261-13. Epub 2013 Apr 9.
引用本文的文献
1
Evaluating Effects of Antibiotics Across Preclinical Models of the Human Gastrointestinal Microbiota.评估抗生素对人类胃肠道微生物群临床前模型的影响。
Microbiologyopen. 2025 Aug;14(4):e70030. doi: 10.1002/mbo3.70030.
2
Perturbations in the gut microbiome of C57BL/6 mice by the sobriety aid Antabuse® (disulfiram).戒酒辅助药物安塔布司（双硫仑）对C57BL/6小鼠肠道微生物群的扰动。
J Appl Microbiol. 2025 Jan 6;136(1). doi: 10.1093/jambio/lxae305.
3
Sepsis Management in Southeast Asia: A Review and Clinical Experience.东南亚地区的脓毒症管理：综述与临床经验
J Clin Med. 2022 Jun 23;11(13):3635. doi: 10.3390/jcm11133635.
4
Metronidazole Delivery Nanosystem Able To Reduce the Pathogenicity of Bacteria in Colorectal Infection.甲硝唑递药纳米系统能够降低结直肠感染中细菌的致病性。
Biomacromolecules. 2022 Jun 13;23(6):2415-2427. doi: 10.1021/acs.biomac.2c00186. Epub 2022 May 27.
5
Design and Comparative Evaluation of Vancomycin HCl-Loaded Rosin-Based In Situ Forming Gel and Microparticles.盐酸万古霉素负载的松香基原位形成凝胶和微粒的设计与比较评价
Gels. 2022 Apr 8;8(4):231. doi: 10.3390/gels8040231.
6
Computational modeling of the gut microbiota reveals putative metabolic mechanisms of recurrent Clostridioides difficile infection.肠道微生物组的计算建模揭示了复发性艰难梭菌感染的潜在代谢机制。
PLoS Comput Biol. 2021 Feb 22;17(2):e1008782. doi: 10.1371/journal.pcbi.1008782. eCollection 2021 Feb.
7
Droplet-based high-throughput cultivation for accurate screening of antibiotic resistant gut microbes.基于液滴的高通量培养技术用于准确筛选抗生素耐药肠道微生物。
Elife. 2020 Jun 17;9:e56998. doi: 10.7554/eLife.56998.
8
The Quest for Novel Antimicrobial Compounds: Emerging Trends in Research, Development, and Technologies.新型抗菌化合物的探索：研究、开发与技术的新趋势
Antibiotics (Basel). 2019 Jan 24;8(1):8. doi: 10.3390/antibiotics8010008.
9
Sub-lethal doses of surotomycin and vancomycin have similar effects on Clostridium difficile virulence factor production in vitro.低致死剂量的苏罗替莫星和万古霉素对体外艰难梭菌毒力因子产生有相似的影响。
J Med Microbiol. 2018 Dec;67(12):1689-1697. doi: 10.1099/jmm.0.000852. Epub 2018 Oct 11.
10
A Small Molecule-Screening Pipeline to Evaluate the Therapeutic Potential of 2-Aminoimidazole Molecules Against .一种用于评估2-氨基咪唑分子治疗潜力的小分子筛选流程 针对……
Front Microbiol. 2018 Jun 6;9:1206. doi: 10.3389/fmicb.2018.01206. eCollection 2018.
本文引用的文献
1
Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection.疑似艰难梭菌感染患者口服万古霉素的粪便药代动力学。
BMC Infect Dis. 2010 Dec 30;10:363. doi: 10.1186/1471-2334-10-363.
2
Management of Clostridium difficile infection: thinking inside and outside the box.艰难梭菌感染的管理：跳出固有思维。
Clin Infect Dis. 2010 Dec 1;51(11):1306-13. doi: 10.1086/657116. Epub 2010 Oct 27.
3
A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin.一种新型大环抗生素，非达霉素（OPT-80），相较于万古霉素，引起艰难梭菌感染患者肠道微生物群改变更小。
Microbiology (Reading). 2010 Nov;156(Pt 11):3354-3359. doi: 10.1099/mic.0.042010-0. Epub 2010 Aug 19.
4
Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium difficile infection.在医疗机构相关性艰难梭菌感染爆发期间，优先使用万古霉素治疗时，并未发现万古霉素耐药肠球菌定植增加。
Infect Control Hosp Epidemiol. 2010 Jul;31(7):710-5. doi: 10.1086/653613.
5
Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection. fidaxomicin (OPT-80) 治疗艰难梭菌感染。
Expert Opin Pharmacother. 2010 Jun;11(9):1569-78. doi: 10.1517/14656566.2010.485614.
6
Clostridium difficile infection: new developments in epidemiology and pathogenesis.艰难梭菌感染：流行病学与发病机制的新进展
Nat Rev Microbiol. 2009 Jul;7(7):526-36. doi: 10.1038/nrmicro2164.
7
Review of current literature on the economic burden of Clostridium difficile infection.艰难梭菌感染经济负担的当前文献综述。
Infect Control Hosp Epidemiol. 2009 Jan;30(1):57-66. doi: 10.1086/592981.
8
The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing.深度16S rRNA测序揭示了抗生素对人类肠道微生物群的广泛影响。
PLoS Biol. 2008 Nov 18;6(11):e280. doi: 10.1371/journal.pbio.0060280.
9
OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection.OPT-80可清除艰难梭菌，且在治疗艰难梭菌感染期间对拟杆菌属菌种无损害。
Antimicrob Agents Chemother. 2009 Jan;53(1):261-3. doi: 10.1128/AAC.01443-07. Epub 2008 Oct 27.
10
Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease.在艰难梭菌相关性疾病的治疗过程中，口服甲硝唑和口服万古霉素均会促使耐万古霉素肠球菌持续过度生长。
Antimicrob Agents Chemother. 2008 Jul;52(7):2403-6. doi: 10.1128/AAC.00090-08. Epub 2008 Apr 28.
Zotero 插件